Member Info for crumbs

Little Brad Loncar NASDAQ trade-talk interview .... I presume it would be NASDAQ our mates BioNtech would opt to IPO on... wonder what about AIM would put them off tee hee gufffawwww! :) anyways interesting little interview about state of Immunotherapy market etc... obviously totally US focused
https://twitter.com/bradloncar/status/1093612270633005057

part of their IPO attractiveness would be to have a TCR trial ready to go...

DA its not new news in as much as it has been looking like they were heading that way.... so there is a valuation $5billion.... no ph3 assets either... tellling ya scancell is the poundland BioNtech :) be interesting to follow that story and hopefully they are not too distracted to get on with our licensing deal!

patents not parents lol

Scancells understanding of moditope grows and grows and they reveal more (probably due to parents being in place)
What a wonderful yet simple platform... It basically kickstarts a mechanism that already within us...no blocking pathways or adding toxins or blind targetting... simple...

'Responses are rapidly detected post vaccination suggesting they are preexisting and cause swift regression of large tumours within 4 days'

Tumours are gone in 4 days!..... and we know they do not come back...memory response
'These cytotoxic CD4 T cells really are amazing' L. Durrant

Let us hope having been in his labs for a year prof Sahin is thinking exactly the same..... very excited about getting moditope into the clinic especially considering the targets...come on team scancell

Yeah, dunno... but in theory, TCR licensing upfront ought to give scancell enough not to worry about it... better to hold onto that IP if we are confident of success... Lindy sure sounds it.... of course, if an offer that can not be refused appeared better not to refuse it.... at the minute we have nowt lol

I think that might be you lol ... anyways is a nice little article... and just wondered if beyond the modi1 'trial' which we know of if further 'trials' might be in the planning that was all:)

Still does not make a 'trial' ... 'trials' lol

Oh I remember that lol... lets not go there :) but who knows might be Modi1 TCR trial/s being planned too

From Lindy and Ruhuls article.. may mean nothing but they say 'clinical trials'... well we know of a 'trial' but 'trials' ?...

'Furthermore, CD4-specific
responses were also observed when these peptides were
tested in vitro using PBMCs from healthy individuals with
several HLA types. The results from PMBCs proliferation
assays suggest the citrullination-specific response is not
restricted to just one HLA type, hence the vaccine can be
used in a wider population. Clinical trials with MODI-1
are now being designed. '

'... we must be due some good news soon ...'

Amen to that!...

Seems a lot of testing has been going on in both healthy donor blood and cancer patients... and the CD4+ response is there... bodes well for the coming trial I would say

It is on the recent poster
http://www.scancell.co.uk/file-manager/scientific-papers/ruhul-choudhury-poster-jan-19.pdf

What you reckon?

? Citrullinated Vimentin and a-Enolase peptides can stimulate CD4 T
cell response. CD25 depletion can unmask or enhance responses.
? Proliferating CD4 T cells express activation marker CD134, IFN? and
Granzyme B.
? CD4 responses are highly clonal and showed TEMRA (highly cytotoxic
effector memory cells) or effector memory phenotype.
? Some donors showed a pre-existing (memory) responses to
citrullinated peptides.
? Repertoire to citrullinated peptides exists in cancer patients that
could potentially be boosted by immunization to assist in tumor
eradication.

To watch the emergence of team science scancell LD's test tube babies :)

Snappy title

'Cancer vaccine: how far
are we from curing cancer?'

By our Linds and new(ish) guy...Ruhuly

http://www.portlandpresspublishing.com/sites/default/files/biochemist/Biochemist%20Immunology%20issue/BioFEB19Web_Choudhury%29.pdf

http://www.scancell.co.uk/file-manager/scientific-papers/cri-2018-antiglycan-antibodies.pdf
Targeting gastrointestinal tumors with constant region - engineered
anti - glycan antibodies

http://www.scancell.co.uk/file-manager/scientific-papers/ruhul-choudhury-poster-jan-19.pdf

Healthy individuals have a repertoire of CD4 cells that
recognize and respond to citrullinated peptides – a possible
new target for cancer immunotherapy?

And another

Abstract B102: Pre-existing citrulline-specific CD4 T-cells can be efficiently harnessed for tumor therapy
http://cancerimmunolres.aacrjournals.org/content/7/2_Supplement/B102